Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics reported a Q1 2026 net loss of $22.4 million on total revenue of $35.1 million, up from $30.0 million a year earlier. Product revenue from XPOVIO rose to $29.2 million, while license and other revenue declined to $5.9 million.
The company ended the quarter with $90.9 million in cash and cash equivalents and total assets of $131.4 million against total liabilities of $397.1 million, leaving a stockholders’ deficit of $265.6 million and an accumulated deficit of $1.8 billion.
Management concludes there is substantial doubt about the ability to continue as a going concern within one year, given ongoing losses, significant debt, required minimum liquidity covenants, and uncertainty around new funding or strategic alternatives. Recent financing included $26.9 million from a private placement and $19.8 million from at-the-market share sales, plus amendments and forbearance on term loan and convertible notes.
Karyopharm Therapeutics reported first quarter 2026 results with total revenue of $35.1 million, up from $30.0 million a year earlier. U.S. XPOVIO net product revenue rose to $29.2 million from $21.1 million, helped by lower gross-to-net adjustments, while royalty revenue increased to $1.9 million.
Operating loss improved to $26.8 million and net loss narrowed to $22.4 million, or $1.02 per basic share. The company reaffirmed 2026 total revenue guidance of $130–$150 million and U.S. XPOVIO revenue of $115–$130 million, and expects its cash to fund operations into late in the third quarter of 2026.
Karyopharm highlighted clinical milestones, including completion of enrollment in the Phase 3 XPORT-EC-042 endometrial cancer trial and positive Phase 3 SENTRY myelofibrosis results that met the spleen volume reduction endpoint but not the symptom score endpoint. Topline data readouts from multiple Phase 3 trials are expected in mid to second half of 2026.
Adage Capital Management and affiliated reporting persons disclose beneficial ownership of 1,821,736 shares of Karyopharm Therapeutics common stock, representing 8.08% of the class. This percentage is calculated on an aggregate of 22,543,316 shares outstanding as of March 26, 2026 and assumes exercise of warrants exercisable for 15,414 shares held by Adage Capital Partners, L.P.
The filing attributes shared voting and shared dispositive power for the reported shares to the reporting persons and lists the reporting entities and individuals (Adage Capital Management, L.P.; Robert Atchinson; Phillip Gross) with their Boston business address. Signatures are dated May 13, 2026.
The Goldman Sachs Group, Inc. filed a Schedule 13G reporting shared voting and dispositive power over 991,363.52 shares of THERAPEUTICS INC. (CUSIP 48576U205) representing 5.1% of the class as of 03/31/2026.
The filing is a joint disclosure with Goldman Sachs & Co. LLC and includes a Joint Filing Agreement plus exhibits describing the parent/subsidiary reporting structure and customary disclaimers about client accounts.
Karyopharm Therapeutics Inc. ownership update: Opaleye entities report beneficial ownership of 619,089 shares of common stock issuable upon exercise of warrants, immediately exercisable, representing 2.67% of the class as of March 31, 2026. The percentage is calculated using 22,543,316 shares outstanding as of March 26, 2026 plus the shares issuable upon exercise. The statement is filed by Opaleye Management Inc., Opaleye, L.P., and James Silverman with respect to warrants directly held by the Fund.
Karyopharm Therapeutics Inc. filed a registration statement to register the resale of up to 8,843,036 shares of its common stock. The shares consist of 1,030,354 outstanding shares, 3,391,164 shares issuable upon exercise of pre-funded warrants and 4,421,518 shares issuable upon exercise of warrants. The company will receive no proceeds from resale; it agreed to pay registration expenses pursuant to a registration rights agreement related to a March 2026 private placement that generated approximately $30 million in gross proceeds. The prospectus discloses a 9.99% beneficial ownership limitation on warrant exercises and describes distribution methods including ordinary brokerage transactions, block trades and privately negotiated sales.
Karyopharm Therapeutics Inc. filed a shelf registration on Form S-3 to offer up to $400,000,000 of securities, including debt, common stock, preferred stock, units and warrants. The filing includes an at-the-market sales agreement with Jefferies to sell up to $100,000,000 of common stock from time to time. The prospectus describes general terms and states proceeds will be used for general corporate purposes. The document incorporates prior SEC reports by reference and discloses an Ernst & Young LLP audit opinion noting an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported a small, non-discretionary sale of common stock tied to taxes on vested equity. On April 21, 2026, a broker-assisted sale of 449 shares of common stock was executed at $8.94 per share.
According to the disclosure, this trade was carried out under a durable automatic sale instruction plan adopted on April 4, 2022 and was used to satisfy withholding tax liability from the vesting of restricted stock units. After this transaction, Rangwala directly holds 56,290 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. ownership update: three affiliated Millennium entities and Israel A. Englander report shared beneficial interests in common stock as of 03/31/2026. Integrated Core Strategies (US) LLC reports 423,982 shares (1.9%); Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report 511,571 shares (2.3%). The filing states these holdings are subject to shared voting and dispositive power and includes a joint filing agreement dated April 10, 2026.